检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:杨军[1] 王苏燕[1] 丁赛良[1] 王光辉[1] 邓彪[1] 张勇[1] 褚春[2] 伍卫[3]
机构地区:[1]南华大学附属第一医院心内科,衡阳421001 [2]南华大学附属第二医院药剂科,衡阳421001 [3]中山大学附属第二医院心内科
出 处:《中华老年心脑血管病杂志》2012年第3期307-310,共4页Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
基 金:中华医学会临床医学科研专项基金(09010280183);湖南省科技厅重点课题(2009SK2010)
摘 要:目的研究血管紧张素Ⅱ(AngⅡ)刺激心肌细胞肥大后,缝隙连接蛋白43(Cx43)表达的变化及缬沙坦的干预作用。方法分离培养大鼠心肌细胞,分为对照组,AngⅡ组(Ang1Ⅱ1.0×10^-6mol/L)和缬沙坦组(AngⅡ1.0×10^-6mol/L+缬沙坦1.0×10^-6mol/L)。另外将缬沙坦以1.0×10^-5、1.0×10^-6和1.0×10^-7mol/L刺激分为A组、B组和C组。先用AngⅡ诱导心肌肥大24h后,采用免疫荧光法和免疫印迹蛋白法观察心肌细胞Cx43蛋白表达以及缬沙坦的干预作用。结果与对照组比较,AngⅡ组心肌细胞明显肥大,蛋白质含量明显增加,Cx43蛋白表达明显上调;与AngⅡ组比较,缬沙坦纽拮抗AngⅡ刺激下Cx43蛋白的上调,并呈明显浓度依赖性下降。与A组比较,B、C组Cx43蛋白表达下降(P〈0.05)。结论AngⅡ刺激心肌细胞24h后,通过AngⅡ1型受体信号通路,导致Cx43蛋白表达浓度依赖性上调,缬沙坦明显抑制其上调,Cx43上调可能与心肌肥大过程有关。Objective To study the inte (Cx43) protein in angiotensin Ⅱ (Ang diomyoeytes were randomly divided int 10 6 mol/L valsartan group which wa (group A), 1.0× 10 (group C). Intervent h exposure to Ang Ⅱ suits group down- Ang 11 6 ion The expression than in control mol/L effect valsarta rvention effect of valsartan on expression of conne Ⅱ)-stimulated cardiomyocytes. Methods Cultured r o control group, 1.0× 10 6 mol/L Ang Ⅱ group, and s further divided into 1. 0 N 10 -5 mol/I, valsartan n group(group B0,and 1.0×10 7mol/L valsartan xin 43 at car 1.0× group group of valsartan on Cx43 protein expression in cardiomyocytes after 24 was detected by flow cyt level of Cx43 protein in group an regulates the expression receptor signal pathway. ometry and immuno cardiomyocytes was fluorescence, respectively. Resignificantly higher in Ang Ⅱd valsartan group. Conclusion Ang Ⅱ up-regulates and valsartan of Cx43 protein in a dose-dependent manner through the type I Up-regulated expression of Cx43 protein may be related with hypertrophy of cardiomyocytes.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:18.220.154.82